NATHBIOGEN Nath Bio-Genes (India) Q2 FY26 results (Jul–Sep 2025) and concall
Nath Bio-Genes reported strong H1 FY26 results with revenue growing 15.9% YoY and PAT increasing 15.3% YoY to INR424 million, driven by robust performance in cotton, maize, and vegetable seeds. While gross profit expanded, EBITDA margin saw some compression due to marketing schemes. The company continues to focus on product innovation and R&D to drive future growth, despite challenges from climate unpredictability and illegal seed markets.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 25.0%, net profit up 33.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 32 | 37 | 49 | 280 | 40 +25% |
| EBITDA | 7 | 8 | 3 | 30 | 7 +0% |
| Net profit | 3 | 3 | 5 | 29 | 4 +33% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
